Evidence map›Paper›PMID 42832063›Full record

ArticleJournal of gastroenterology2026

Healthcare burden and clinical spectrum of symptomatic polycystic liver disease in Japan: a nationwide epidemiological survey.

Kota Tsuruya, Satoko Ohfuji, Tatsuya Suwabe, Yusuke Mishima, Yoshitaka Arase, Shunji Hirose, Satsuki Ieda, Junichi Hoshino, Shintaro Yagi, Kiyoshi Hasegawa and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kota TsuruyaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, 259-1193, Japan. ktsuruya@tokai.ac.jp.ORCID http://orcid.org/0000-0002-9884-8039
Satoko OhfujiDepartment of Public Health, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Tatsuya SuwabeNephrology Center, Toranomon Hospital, Tokyo, Japan.
Yusuke MishimaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, 259-1193, Japan.
Yoshitaka AraseDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, 259-1193, Japan.
Shunji HiroseDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, 259-1193, Japan.
Satsuki IedaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, 259-1193, Japan.
Junichi HoshinoDepartment of Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
Shintaro YagiDepartment of Hepato-Biliary-Pancreatic Surgery and Transplantation, Kanazawa University, Kanazawa, Japan.
Kiyoshi HasegawaArtificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Atsushi TanakaDepartment of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Tatehiro KagawaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, 259-1193, Japan.

Funding

Ministry of Health and Welfare, Japan JPMH20FC1023
6 · The paper itself

Abstract

backgroundPolycystic liver disease (PLD) is often asymptomatic, but some patients develop symptoms or complications requiring care or intervention. The nationwide burden of symptomatic PLD remains poorly defined. We conducted a nationwide survey to estimate the number and prevalence of patients with symptomatic PLD in Japan and characterize clinical features, treatment patterns, healthcare utilization, and outcomes.

methodsA nationwide two-stage questionnaire survey was conducted. Symptomatic PLD was defined as 10 or more hepatic cysts with cyst-related symptoms or complications. In the first-stage survey, 3127 departments were selected by stratified random sampling to estimate the number of patients treated or followed up during 2021-2023. In the second-stage survey, clinical data were collected for patients treated or followed up in 2023.

resultsThe estimated number of patients was 6500 during 2021-2023 and 3570 in 2023, corresponding to an annual prevalence of 28.6 per million. Among 557 patients with clinical data, 62% were female and 67.2% met the diagnostic criteria for polycystic kidney disease. Abdominal distension, abdominal pain, and cyst infection were the most frequent manifestations. More than half underwent hepatic cyst treatment, and 60.4% required consultation with other departments or institutions. Cyst infection and liver failure accounted for a subset of deaths. Mortality differed significantly among Gigot classification groups and was highest in type III.

conclusionsThis nationwide survey provides the first comprehensive epidemiological and clinical characterization of symptomatic PLD in Japan and establishes a benchmark for future disease severity classification, clinical management, and prospective studies.

Indexed as

EpidemiologyHepatic cystNationwide surveyPolycystic liver diseaseTreatment

Identifiers

PMID42832063

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.